REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of “Moderate Buy” by Analysts
REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has been given an average rating of “Moderate Buy” by the twelve ratings firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 1-year price […]
More Stories
FBI Identifies Suspect in Palm Springs Fertility Clinic Bombing
By Jack Phillips An FBI official said on May 18 that the bureau believes that it has identified the suspect...
Federal Officials Start Investigation Into Mexican Tall Ship That Hit Brooklyn Bridge
By Jack Phillips Federal officials confirmed on May 18 that they are sending a team to investigate the Mexican Navy...
Market Review: Stocks Roar Back in 5-Day Winning Streak
By Panos Mourdoukoutas News Analysis U.S. stocks roared back this week, with the S&P 500 Index scoring a five-day winning...
Trump to Call Putin and Zelenskyy Monday in Bid to End Ukraine War
By Tom Ozimek President Donald Trump said he plans to speak by phone with Russian President Vladimir Putin on the...
PGA Championship: Scottie Scheffler overcomes scare to run away with third career major
By Jay Busbee CHARLOTTE, N.C. — Scottie Scheffler has spent the last year and a half further establishing himself as...
FDA Approves New COVID-19 Vaccine, With Restrictions
By Jacob Burg Novavax’s new COVID-19 vaccine received long-awaited approval from the Food and Drug Administration (FDA) on May 16,...